This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market
by Zacks Equity Research
Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
HealthEquity (HQY) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2025.
Inari's (NARI) Expanding Product Portfolio Offsets Competition
by Zacks Equity Research
Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.
DexCom (DXCM) Declines on Potential Competition for Stelo
by Zacks Equity Research
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
by Zacks Equity Research
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
by Zacks Equity Research
Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe
by Zacks Equity Research
Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Strength in HSA Likely to Aid HealthEquity's (HQY) Q1 Earnings
by Zacks Equity Research
Continued strength in HSA, aided by transfers of HSA Assets from BenefitWallet, is likely to have boosted HealthEquity's (HQY) top line in the fiscal first quarter.
Stryker (SYK) Issues Safety Notice for Its Total Knee System
by Zacks Equity Research
Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Intuitive Surgical (ISRG) Stock Gains 20% YTD: Here's Why
by Zacks Equity Research
Intuitive Surgical (ISRG) shares gain on the back of growth in the da Vinci treatment volume and raised procedure prices.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. Gross margins improve. However, the rising cost of products is a concern.
ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) led by strong growth in the U.S. mask and accessories business and its cloud-connected platforms.
Inari Medical (NARI) Sues Truvic on Patent Infringement
by Zacks Equity Research
Inari Medical (NARI) files a patent infringement lawsuit against Imperative Care and its subsidiary Truvic over intentionally copying and overlapping the designs of Inari Medical's products.
Integer Holdings (ITGR) Gains 23.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Integer Holdings (ITGR) shares soar on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
by Zacks Equity Research
Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.
Why Is Align Technology (ALGN) Down 18.7% Since Last Earnings Report?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock.
Intuitive Surgical (ISRG) Hits 52-Week High on Procedure Demand
by Zacks Equity Research
Intuitive Surgical's (ISRG) da Vinci procedure volume, coupled with strong Ion procedure growth, is fueling the rally in the company???s share price.